[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yongxin Zhou\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100592605","impact-of-thoracic-duct-ligation-on-postoperative-weight-reduction-in-obese-patients-receiving-minimally-invasive-lung-surgery-a-clinical-investigation-100592605",false,"NCT06995599","Impact of Thoracic Duct Ligation on Postoperative Weight Reduction in Obese Patients Receiving Minimally Invasive Lung Surgery: A Clinical Investigation","Thoracic Duct Ligation and Postoperative Weight Loss in Obese Patients Undergoing Minimally Invasive Lung Surgery: A Pilot Exploratory Clinical Study","Inclusion Criteria:\n\n1. Age \\& Gender: Individuals aged 18-75 years, regardless of gender.\n2. Clinical Profile:Diagnosed with early-stage lung cancer (stage IA1-IB) and obesity (BMI ≥28 kg\u002Fm²).\n3. Scheduled to undergo video-assisted thoracoscopic surgery (VATS) for right-sided lung cancer resection at our institution between October 2024 and October 2026.\n4. Surgical Eligibility: Approved for surgery following multidisciplinary team (MDT) assessment.\n5. Treatment Plan: No requirement for adjuvant therapy post-lung resection.\n6. Preoperative Evaluation:Completed standard preoperative workup, including:\n7. Chest CT、Brain CT\u002FMRI、Abdominal ultrasound OR PET-CT to rule out distant metastasis.\n8. Informed Consent: Willing and able to comply with study requirements, with written informed consent provided.\n\nExclusion Criteria:\n\n1. Concurrent Thoracic Infections: Patients with active intrathoracic infectious diseases (e.g., inflammatory conditions, tuberculosis).\n2. Refusal of Novel Technique: Patients unwilling to undergo intraoperative thoracic duct ligation.\n3. Clinically Unstable Comorbidities: Severe, unstable cardiovascular, renal, or respiratory disorders.\n4. Prior Bariatric Surgery: History of weight-loss surgery (e.g., gastric bypass, sleeve gastrectomy).\n5. Recent Trial Participation: Enrollment in other clinical trials within 30 days prior to screening.\n6. Investigator Discretion: Other conditions deemed by the investigator to contraindicate participation.","ALL","18 Days","75 Days",{"count":20,"type":21},16,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical trial aims to investigate whether thoracic duct ligation (TDL) can improve obesity and lipid metabolism. The primary questions it seeks to answer are:\n\nWhether thoracic duct ligation can improve BMI and lipid metabolism in obese patients.\n\nThe safety and feasibility of thoracic duct ligation as a treatment for obesity.",[27],"Obese Patients",[29,30,31],"Obesity","therapy","Metabolic Effects of Thoracic Duct Ligation","NOT_YET_RECRUITING","2025-05-21",{"date":35,"type":36},"2025-05-29","ACTUAL",{"date":38,"type":21},"2025-06-01",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Yongxin Zhou","OTHER",""]